AstraZeneca vaccine benefits still ‘largely positive’

AstraZeneca vaccine benefits still ‘largely positive’
AstraZeneca vaccine benefits still ‘largely positive’

We show you our most important and recent visitors news details AstraZeneca vaccine benefits still ‘largely positive’ in the following article

Hind Al Soulia - Riyadh - GENEVA — The benefits of the AstraZeneca COVID-19 vaccine are still “largely positive” and outweigh risk of rare but serious blood clots, according to an official with the World Health Organization (WHO), speaking on Tuesday during the agency’s regular press briefing from Geneva.

Dr Rogério Pinto de Sá Gaspar, director for regulation and prequalification, was responding to a journalist’s question regarding links between the vaccine and cerebral venous sinus thrombosis, a rare blood clotting syndrome.

The European Medicines Agency (EMA) on Tuesday denied that it had established any link, following reports that one of its experts stated there was a connection.

Expert meetings underway

Meanwhile, an EMA committee that monitors the safety of medicines has been meeting to assess the data, which is also being reviewed by a regulatory body in the United Kingdom. WHO is following both proceedings.

“What we can say is that the appraisal that we have for the moment, and this is under consideration by the experts, is that the benefit risk assessment for the vaccine is still largely positive,” said Dr. Pinto de Sá Gaspar.

He reported that “thrombolytic events” are rare, and are now being categorized in terms of their distribution within the population.

“For the time being, there is no evidence that the benefit risk assessment for the vaccine needs to be changed”, he added. “And we know from the data coming from countries like the UK and others, that the benefits are really important in terms of reduction of the mortality of populations that are being vaccinated.”

WHO’s Global Advisory Committee on Vaccine Safety is due to meet on Wednesday, which also will look at the data, with a conclusion expected later in the week.

Stigma and virus variants

WHO continues to work with a group of scientists worldwide to develop nomenclature for variants of the new coronavirus that causes COVID-19.

Many people, including health experts, have been referring to the variants by the countries in which they were first detected, something the UN agency wants to change.

“We need to make sure that any of the names that are used do not further stigmatize a person, or a last name, or a location, inadvertently”, said Dr. Maria Van Kerhove, WHO technical lead on COVID-19, responding to a question from a South African journalist.

“There should be no stigma associated with these viruses being detected, and unfortunately we still see that happening.”

Currently there are three variants: B117, first identified in the UK; B 1.351, which was first identified in South Africa, and P1, a variant first detected in Japan but circulating in Brazil. — UN News


These were the details of the news AstraZeneca vaccine benefits still ‘largely positive’ for this day. We hope that we have succeeded by giving you the full details and information. To follow all our news, you can subscribe to the alerts system or to one of our different systems to provide you with all that is new.

It is also worth noting that the original news has been published and is available at Saudi Gazette and the editorial team at AlKhaleej Today has confirmed it and it has been modified, and it may have been completely transferred or quoted from it and you can read and follow this news from its main source.

PREV Americans given life sentences for murder of police officer in Rome
NEXT US calls on Israelis, Palestinians to ‘deescalate’ tensions